Can someone help me understand if they beat? Looks like they missed on revenue, but hit on the bottom line big. Is that a right or wrong assessment?
Sorry to be harsh here, but they just failed a Phase III trial on a $500m+ indication. Who cares about a beat or not on earnings?I reckon this will be down 30% tomorrow.They do have another Phase III read-out on a reduced BROMDAY dosage in Q4 2011, so a swinging stockmarket reaction over the next few days could actually represent a decent entry point.
good call, dude.
what is good entry point? thanks.